MedTrace Logo

Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

NCT05682560 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-03-24

No results posted yet for this study

Summary

REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.

Conditions

  • Long COVID
  • Post-COVID Syndrome
  • Post COVID-19 Condition

Interventions

BIOLOGICAL

REGENECYTE

HPC, Cord Blood

BIOLOGICAL

Placebo

Normal Saline

Sponsors & Collaborators

  • StemCyte Taiwan Co., Ltd.

    collaborator INDUSTRY

  • StemCyte, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-04
Primary Completion
2024-07-26
Completion
2025-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05682560 on ClinicalTrials.gov